C19orf48P and glioblastoma: It is known to display excellent antineoplastic activity in GBM cells in vitro but poor efficacy in vivo due to extrusion by multidrug resistance-related proteins present on both BBB and GBM cells.39 To constrain DOXO severe adverse effects such as cardiotoxicity and myelosuppression FDA-approved liposomal DOXO formulations are currently in use in the clinic.